Transcatheter tricuspid valve‐in‐valve implantation for degenerative surgical bio‐prosthesis using SAPIEN 3: A case series

We evaluated early outcomes of transcatheter valve‐in‐valve (ViV) implantation in patients with degenerated bio‐prosthesis in tricuspid position. Total of 5 patients were included in our case series. Baseline native tricuspid valve etiology were highly varied ranging from chest wall trauma, Ebstein anomaly, rheumatic heart disease, infective endocarditis and complex congenital heart disease. These differences also made patient comorbidities highly varied. Procedure details were also varied due to different clinical and technical challenges. All cases underwent successful Tricuspid VIV implantation with satisfactory hemodynamics results. All patients experienced improved clinical symptoms at follow up.     

丁公藤碱Ⅱ降眼压和缩瞳作用的研究

用双盲法研究观察丁公藤碱Ⅱ滴剂(碱Ⅱ),对原发性开角青光眼72例(144眼)的降眼压和缩瞳作用。结果表明0.01％、0.05％碱Ⅱ的降眼压和缩瞳作用同1％毛果芸香碱液相似。长期滴用无明显的副作用和毒性。实验室研究表明碱Ⅱ在兔眼发生降眼压和缩瞳的同时,伴有房水c-GMP的升高。     

氩激光小梁成形术治疗开角型青光眼——4年随访报告(摘要)

用氩激光小梁成形术(ALT)治疗79例105眼开角型青光眼的4年疗效。总有效率78％,平均眼压下降1.34kPa(10.04mmHg),4年内疗效稳定。全部病例均为最大耐受量药物治疗无效拟作滤过性手术者,ALT术后83％病例在4年内可避免作滤过性手术。失败的23眼中有21眼在ALT后半年内眼压回升,另2眼在第3年回升,18眼(17％)须作滤过性手术。ALT术后42.9％的病例其用药种数减少。年岁较大(>60岁)、眼压<4.0kPa(30mmHg)且病情较轻者则疗效较佳;严重损害的晚期青光眼(C/D≥0.9,视野<20°)对ALT的反应较差,近60％在ALT术后仍须作滤过性手术。